论文部分内容阅读
目的总结了我院初治１１５例急性淋巴细胞白血病（ＡＬＬ）及３０例急性髓性白血病（ＡＭＬ）的诱导缓解治疗效果，同时介绍了早期巩固强化治疗方案。方法ＡＬＬ诱导化疗方案：病人共分三组：（１）ＣＯＰ，（２）ＣＯＰ＋ＤＮＲ，（３）ＣＯＰ＋ＩＤＡ。以第８天骨髓象＜５％为良好快速早期反应（ｒａｐｉｄｅａｒｌｙｒｅｓｐｏｎｓｅ，ＲＥＲ）的标准。ＡＭＬ诱导缓解治疗方案为ＡＤ＋ＶＰ１６。结果三组ＲＥＲ良好的百分率分别为：６８３％，７５７％，９０９％。第一组与第三组之间Ｐ＜００５，疗效存在显著性差异。ＡＭＬ一个疗程达到完全缓解的占９０％。结论可供分析无病生存期的ＡＬＬ病例共６０例，无病生存达４年以上者占８５％（５１／６０）。ＡＭＬ共３０例，无病生存达４年以上者占７０％（２１／３０）。
Objective To summarize the therapeutic effect of induction therapy of 115 cases of acute lymphoblastic leukemia (ALL) and 30 cases of acute myeloid leukemia (AML) in our hospital at the early stage, and introduce the treatment of early consolidation and intensive treatment. Methods ALL chemotherapy regimens: patients were divided into three groups: (1) COP, (2) COP + DNR, (3) COP + IDA. The standard of good rapidear response (RER) on day 8 is myeloid <5%. AML induced remission treatment program for the AD + VP16. Results The good percentage of RER in three groups was 683%, 757% and 909% respectively. Between the first group and the third group P <0 05, there are significant differences in the efficacy. AML 90% complete remission of a course of treatment. Conclusions There were 60 ALL patients with disease-free survival and 85% (51/60) patients with disease-free survival of 4 years or more. AML a total of 30 cases, disease-free survival of more than 4 years accounted for 70% (21/30).